Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
UncategorizedMarch 24, 2022
Our employees are passionate, innovative, and collaborative. Together, we strive to relieve suffering for people with great needs, but few options.
Tardive dyskenisia (TD) is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) financial results for the second quarter ended June 30, 2022 and reiterated financial guidance for 2022.